Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.
Liu W, Huang W, Wang M, Lv R, Li J, Wang Y, Deng S, Yi S, Liu H, Rao Q, Xu Y, Lv L, Qiu L, Zou D, Wang J.
Liu W, et al. Among authors: qiu l.
Br J Haematol. 2020 Oct;191(1):126-129. doi: 10.1111/bjh.16951. Epub 2020 Jul 15.
Br J Haematol. 2020.
PMID: 32671820
Free article.
Clinical Trial.
No abstract available.